Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?

Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Rigel Pharmaceuticals (RIGL) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The Zacks Rank system, which complements the Style Scores, rates RIGL as 2 (Buy), suggesting potential for outperformance in the market [4] Price Performance - RIGL shares have increased by 9.25% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 4.43% during the same period [6] - Over the last quarter, RIGL shares have gained 25.28%, and over the past year, they have surged by 82.02%, while the S&P 500 has only increased by 5.77% and 13.9%, respectively [7] Trading Volume - The average 20-day trading volume for RIGL is 631,925 shares, which serves as a baseline for assessing price movements; rising prices with above-average volume are typically bullish [8] Earnings Outlook - In the past two months, three earnings estimates for RIGL have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $5.49 to $6.54 [10] - For the next fiscal year, two estimates have moved up, while one has been revised down [10] Conclusion - Considering the strong momentum indicators and positive earnings outlook, RIGL is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [12]